Meibomian gland disease

Dry Eye and Ocular Surface Disorders

Volumn , Issue , 2004, Pages 247-267

  Mathers, William D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953749335     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (110)

1. Trevor-Roper PD. The eye and its disorders. 2. The bony orbit, lids and lacrimal apparatus. Int Ophthalmol Clin 1974; 14:26-44.
2. Ozanics VJ, F. Prenatal development of the eye and its adenexa. In: WT Tasman and EA Jaeger, eds. Duane’s Foundations of Clinical Ophthalmoloy. Vol 1. Philadephia: Lippincott, 1993:2-73.
3. Seifert P, Spitznas M. Immunocytochemical and ultrastructural evaluation of the distribution of nervous tissue and neuropeptides in the meibomian gland. Graefes Arch Clin Exp Ophthalmol 1996; 234:648-656.
4. Seifert P, Spitznas M. Vasoactive intestinal polypeptide (VIP) innervation of the human eyelid glands. Exp Eye Res 1999; 68:685-692.
5. Kirch W, Horneber M, Tamm ER. Characterization of meibomian gland innervation in the cynomolgus monkey (Macaca fascicularis). Anat Embryol 1996; 193:365-375.
6. Krenzer KL, Reza Dana M, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000; 85:4874-4882.
7. Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand 2000; 78:146-153.
8. Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000; 84:76-84.
9. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000; 41(12):3732-3742.
10. Esmaeli B, Harvey JT, Hewlett B. Immunohistochemical evidence for estrogen receptors in meibomian glands. Ophthalmology 2000; 107:180-184.
11. LeDoux MS, Zhou Q, Murphy RB, Greene ML, Ryan P. Parasympathetic innervation of the meibomian glands in rats. Invest Ophthal Vis Sci 2001; 42:2434-2441.
12. Hisatake K. Evaporation of water in a vessel. J Appl Physiol 1993; 73:7395-7401.
13. Mathers WD, Lane JA. Meibomian gland lipid, evaporation, and tear film stability. In: Sullivan DA, Stern ME, Tsuboota K, Dartt DA, Sullivan RM, Bromberg BB, eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. New York: Plenum, 1998:349-360.
14. Gilbard JP, Rossi SR, Heyda KG. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology 1989; 96:1180-1186.
15. McCulley JP, Shine WE. The lipid layer: the outer surface of the ocular surface tear film. Biosci Rep 2001; 21:407-418.
16. McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea 2000; 19:650-658.
17. Mathers WD, Daley TE. In vivo observation of the human tear film by tandem scanning confocal microscopy. Scanning 1994; 16:316-319.
18. Rolando M, Refojo MF, Kenyon KR. Tear water evaporation and eye surface diseases. Ophthalmologica 1985; 190(3):147-149.
19. Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci 1992; 33(10):2942-2950.
20. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 1993; 100:347-351.
21. Mathers WD, Binarao G, Petroll M. Ocular water evaporation and the dry eye. A new measuring device. Cornea 1993; 12:335-340.
22. Mathers WD, Daley TE. Tear flow and evaporation in patients with and without dry eye. Ophthalmology 1996; 103:664-669.
23. Mathers WD, Lane JA, Sutphin JE, Zimmerman MB. Model for ocular tear film function. Cornea 1996; 15:110-119.
24. Mathers WD, Lane JA, Zimmerman MB. Assessment of the tear film with tandem scanning confocal microscopy. Cornea 1997; 16:162-168.
25. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol 1982; 94:383-387.
26. Mathers WD, Lane JA, Zimmerman MB. Tear film changes associated with normal aging. Cornea 1996; 15:229-234.
27. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye 1991; 5:395-411.
28. Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. Cornea 1992; 11:334-342.
29. Yokoi N, Mossa F, Tiffany JM, Bron AJ. Assessment of meibomian gland function in dry eye using meibometry. Arch Ophthalmol 1999; 117:723-729.
30. Sullivan DA, Rocha EM, Ullman MD, et al. Androgen regulation of the meibomian gland. Adv Exp Med Biol 1998; 438:327-331.
31. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002; 966:211-222.
32. Sullivan BD, Evans JE, Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Complete androgen insensitivity syndrome: Effect on human meibomian gland secretions. Arch Ophthalmol 2002; 120:1689-1699.
33. Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997; 82:2403-2409.
34. Labrie F, Belanger A, Simard J, Van L-T, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 1995; 774:16-28.
35. Sullivan DA. Sex hormones and Sjogren’s syndrome. J Rheumatol 1997; 24(suppl 50):17-32.
36. Sullivan DA, Edwards JA. Androgen stimulation of lacrimal gland function in mouse models of Sjogren’s syndrome. J Steroid Biochem Molec Biol 1997; 60:237-245.
37. Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjogren’s syndrome. Ann N Y Acad Sci 1999; 876:312-324.
38. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg 2001; 20:199-206.
39. Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol 1998; 438:461-469.
40. Huber-Spitzy V, Baumgartner I, Bohler-Sommeregger K, Grabner G. Blepharitis-a diagnostic and therapeutic challenge. A report on 407 consecutive cases. Graefes Arch Clin Exp Ophthalmol 1991; 229:224-227.
41. Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997; 104:1868-1874.
42. Robin JB, Jester JV, Nobe J, Nicolaides N, Smith RE. In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction. A clinical study. Ophthalmology 1985; 92:1423-1426.
43. Zengin N, Tol H, Gunduz K, Okudan S, Balevi S, Endogru H. Meibomian gland dysfunction and tear film abnormalities in rosacea. Cornea 1995; 14:144-146.
44. Lemp MA, Mahmood MA, Weiler HH. Association of rosacea and keratoconjunctivitis sicca. Arch Ophthalmol 1984; 102:556-557.
45. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982; 89:1173-1179.
46. Crow KD. Chloracne and its potential clinical implications. Clin Exp Dermatol 1981; 6:243-257.
47. Jester JV, Nicolaides N, Kiss-Palvolgyi I, Smith RE. Meibomian gland dysfunction. II. The role of keratinization in a rabbit model of MGD. Invest Ophthalmol Vis Sci 1989; 30:936-945.
48. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin 1987; 27:27-35.
49. Cook EB, Stahl JL, Lowe L, et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based low cytometry: allergics vs. non-allergics. J Immunol Meth 2001; 254:109-118.
50. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 1998; 438:643-651.
51. Tsubota K. Tear dynamics and dry eye. Prog Retinal Eye Res 1998; 17:565-596.
52. Mathers W. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J 2000; 26:159.
53. Tiffany JM. The lipid secretion of the meibomian glands. Adv Lipid Res 1987; 22:1-62.
54. Dougherty JM, McCulley JP. Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. Invest Ophthalmol Vis Sci 1986; 27:52-56.
55. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci 1986; 27:486-491.
56. Shine WE, McCulley JP. The role of cholesterol in chronic blepharitis. Invest Ophthalmol Vis Sci 1991; 32:2272-2280.
57. Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated Staphylococcus aureus growth to chronic blepharitis. Invest Ophthalmol Vis Sci 1993; 34:2291-2296.
58. Shine WE, McCulley JP. Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality. Arch Ophthalmol 1998; 116:849-852.
59. Shine WE, McCulley JP. Association of meibum oleic acid with meibomian seborrhea. Cornea 2000; 19:72-74.
60. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea 1991; 10:277-285.
61. Tetz MR, Klein U, Volcker HE, et al. Staphylococci-associated blepharokerato-conjunctivitis. Ophthalmologe 1997; 94:186-190.
62. Seal D, Ficker L, Ramakrishnan M, Wright P. Role of staphylococcal toxin production in blepharitis. Ophthalmology 1990; 97:1684-1688.
63. McCulley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc UK 1986; 105:314-318.
64. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984; 68:524-528.
65. Seal DV, McGill JI, Jacobs P, Liakos GM, Goulding NJ. Microbial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitis. Br J Ophthalmol 1985; 69:604-611.
66. Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea 1991; 10:50-53.
67. Mates A. Inhibition of Staphylococcus aureus lipase by tetracycline. J Invest Dermatol 1973; 60:150-152.
68. Song CH, Choi JS, Kim DK, Kim JC. Enhanced secretory group II PLA2 activity in the tears of chronic blepharitis patients. Invest Ophthalmol Vis Sci 1999; 40:2744-2748.
69. Schaur RJ, Dussing G, Kink E, et al. The lipid peroxidation product 4-hydroxynonenal is formed by-and is able to attract-rat neutrophils in vivo. Free Radic Res 1994; 20:365-373.
70. Muller K, Hardwick SJ, Marchant CE, et al. Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages. FEBS Lett 1996; 388:165-168.
71. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol 1995; 113:1266-1270.
72. Shimazaki J, Goto E, M. O, Shimura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthamology 1998; 105:1485-1488.
73. Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea 2000; 19:483-486.
74. Tomlinson A, Trees GR, Occhipinti JR. Tear production and evaporation in the normal eye. Ophthalmic Physiol Opt 1991; 11:44-47.
75. Korb DR, Greiner JV, Glonek T, et al. Human and rabbit lipid layer and interference pattern observations. Adv Exp Med Biol 1998; 438:305-308.
76. Korb DR, Baron DF, Herman JP, et al. Tear film lipid layer thickness as a function of blinking. Cornea 1994; 13:354-359.
77. Doane MG. Abnormalities of the structure of the superficial lipid layer on the in vivo dry-eye tear film. Adv Exp Med Biol 1994; 350:489-493.
78. Prydal JI, Campbell FW. Study of precorneal tear film thickness and structure by interferometry and confocal microscopy. Invest Ophthalmol Vis Sci 1992; 33:1996-2005.
79. Prydal JI, Artal P, Woon H, Campbell FW. Study of human precorneal tear film thickness and structure using laser interferometry. Invest Ophthalmol Vis Sci 1992; 33:2006-2011.
80. Jester JV, Rife L, Nii D, Luttrull JK, Wilson L, Smith RE. In vivo biomicroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 1982; 22:660-667.
81. Mathers WD, Daley T, Verdick R. Video imaging of the meibomian gland. Arch Ophthalmol 1994; 112:448-449.
82. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286-290.
83. Lee SH, Tseng SC. Rose bengal staining and cytologic characteristics associated with lipid tear deficiency. Am J Ophthalmol 1997; 124:736-750.
84. Nakamura Y, Sotozono C, Kinoshita S. Inflammatory cytokines in normal human tears. Curr Eye Res 1998; 17:673-676.
85. Thakur A, Willcox MD. Cytokine and lipid inflammatory mediator profile of human tears during contact lens associated inflammatory diseases. Exp Eye Res 1998; 67:9-19.
86. Thygeson P. The etiology and treatment of blepharitis: a study in military personnel. Military Surg 1946; 98:191-203.
87. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 2000; 55:178-183.
88. Angelov O, Wiese A, Yuan Y, Andersen J, Acheampong A, Brar B. Preclinical safety studies of cyclosporine ophthalmic emulsion. Adv Exp Med Biol 1998; 438:991-995.
89. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631-639.
90. Tauber J. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. The Cyclosporine Study Group. Adv Exp Med Biol 1998; 438:969-972.
91. Hassing GS. Inhibition of Corynebacterium acnes lipase by tetracycline. J Invest Dermatol 1971; 56:189-192.
92. McCulley JP. Blepharoconjunctivitis. Int Ophthalmol Clin 1984; 24:65-77.
93. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986; 86:449-453.
94. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44:1165-1170.
95. Marks R, Davies MJ. The distribution in the skin of systemically administered tetracycline. Br J Dermatol 1969; 81:448-451.
96. Li DQ, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pflugfelder SC. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001; 73:449-459.
97. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116:88-92.
98. Barnhorst DA, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996; 103:1880-1883.
99. Cermak JM, Papas AS, Sullivan RM, Dana MR, Sullivan DA. Nutrient intake in women with primary and secondary Sjogren’s syndrome. Eur J Clin Nutr 2003; 57:328-334.
100. Ambrosio RJ, Stelzner SK, Boerner CF, Honan PR, McIntyre DJ. Nutrition and dry eye: the role of lipids. Rev Refrac Surg 2002; August:29-32.
101. Francois CA, Connor SL, Wander RC, Connor WE. Acute effects of dietary fatty acids on the fatty acids of human milk. Am J Clin Nutr 1998; 67:301-308.
102. Francois CA, Connor SL, Bolewicz LC, Connor WE. Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am J Clin Nutr 2003; 77:226-233.
103. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J 1996; 22:209-212.
104. Weller R, Pattullo S, Smith L, Golden M, Ormerod A, Benjamin N. Nitric oxide is generated on the skin surface by reduction of sweat nitrate. J Invest Dermatol 1996; 107:327-331.
105. Greiner JV, Leahy CD, Glonek T, Hearn SL, Auerbach D, Davies L. Effects of eyelid scrubbing on the lid margin. CLAO J 1999; 25:109-113.
106. Smith RE, Flowers CW Jr. Chronic blepharitis: a review. CLAO J 1995; 21:200-207.
107. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001; 45(suppl 2):S227-S239.
108. Fox RI. Sjogren’s syndrome: current therapies remain inadequate for a common disease. Exp Opin Invest Drugs 2000; 9:2007-2016.
109. Luke C, Kearney J. Inexpensive punctal plugs for dry eyes. Austral NZ J Ophthalmol 1992; 20:143.
110. Patel S, Grierson D. Effect of collagen punctal occlusion on tear stability and volume. Adv Exp Med Biol 1994; 350:605-608.